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Executive Summary
 
On January 22, 1998, the Secretary of the Department of Health and Human Services concurred 
with the Advisory Committee on Blood Safety and Availability and indicated that persons who 
may have acquired hepatitis C virus (HCV) infection from blood transfusion be identified 
through lookback notifications, and that other people at risk for HCV infection also should be 
identified. The Secretary requested the Centers for Disease Control and Prevention (CDC) to 
develop a comprehensive plan to address the prevention and control of HCV infection and its 
consequences. 
The National Hepatitis C Prevention Strategy is CDC’s response to this request, and includes 
partnerships and coordination with the Agency for Healthcare Research and Quality (AHRQ), 
Food and Drug Administration (FDA),  Health Care Financing Administration (HCFA), Health 
Resources and Services Administration (HRSA), National Institutes of Health (NIH), Substance 
Abuse and Mental Health Services Administration (SAMHSA), and other federal, state, and 
private sector agencies. This CDC strategy serves to protect the public’s health by preventing 
and controlling HCV infection; enhancing health decisions by providing credible information on 
hepatitis C; and promoting healthy living through strong partnerships with national, State, and 
local organizations in both the public and private sectors. 
The goals of the National Hepatitis C Prevention Strategy are to lower the incidence of acute 
hepatitis C in the United States and reduce the disease burden from chronic HCV infection. 
Achievement of these goals requires: 1) harm reduction programs directed at persons at 
increased risk for infection to reduce the incidence of new HCV infections; 2) counseling, 
testing, and medical evaluation and management of infected persons to control HCV-related 
chronic liver disease; 3) surveillance to evaluate the effectiveness of prevention activities; and 4) 
research to provide answers to questions pertinent to the prevention and control of hepatitis C. 
The principle components of the National Hepatitis C Prevention Strategy are: 
•	 education of health care and public health professionals to improve the identification of 
persons at risk for HCV infection and ensure appropriate counseling, diagnosis, medical 
management, and treatment; 
•	 education of the public and persons at risk for infection about risk factors for HCV 
transmission, and the need for testing and medical evaluation; 
•	 clinical and public health activities to identify, counsel, and test persons at risk for HCV 
infection, and medical evaluation or referral for those found to be infected; 
•	 outreach and community-based programs to prevent practices that put people at risk for 
HCV infection, and to identify persons who need to get tested; 
research to better guide prevention efforts. •	 
surveillance to monitor acute and chronic disease trends and evaluate the effectiveness of 
prevention and medical care activities; and  
•	 
Hepatitis C prevention activities must be accessible to persons receiving health care services in 
both the public and private sectors. The most effective means to prevent HCV infection and its 
consequences is to integrate hepatitis C prevention activities into existing clinical services and 
public health programs, such as those for the prevention and treatment of human 
immunodeficiency virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), sexually 
transmitted diseases (STDs) and drug abuse.  Similar risk factors place persons at risk for 
transmission of the major bloodborne viral infections – HIV, HCV, and hepatitis B virus (HBV). 
Effective implementation of the National Hepatitis C Prevention Strategy should reduce the 
number of new HCV infections, further reduce other bloodborne virus infections, and prevent the 
projected increase in chronic liver disease due to hepatitis C. 
 Hepatitis C Virus Infection in the United States
 
Figure 1. 
Hepatitis C virus (HCV) infection is the most common chronic bloodborne viral infection in the 
United States. First identified in 1988, HCV is the causative agent for what was formerly known 
as non-A non-B hepatitis, and is estimated to have infected as many as 242,000 Americans 
annually during the 1980's.  Since 1989, the annual number of new infections has declined by 
more than 80 percent to approximately 41,000 by 1998.  A national survey (the third National 
Health and Nutrition Examination Survey [NHANES III]) of the civilian, non-institutionalized 
U.S. population found that 1.8 percent of Americans (3.9 million) have been infected with HCV, 
of whom most (2.7 million) are chronically infected with HCV.  These estimates of prevalence 
are likely conservative, because the survey excluded incarcerated and homeless persons, groups 
that have high prevalences of HCV infection. Most infected persons were aged 30-49 years 
when the survey was done in the early 1990s (Figure 1). 
Many of these individuals are not aware of 
their infection and are not clinically ill. 
However, the consequences of chronic liver 
disease from hepatitis C do not become 
apparent until 10 to 20 years after infection. 
Risk factors for infection. Individuals who 
injected drugs, even if they did so on only one 
occasion many years ago, are at highest risk 
for HCV infection (Figure 2). HCV infection 
is rapidly acquired following the initiation of 
injection drug use and occurs from the sharing 
of needles, syringes, or other equipment 
associated with drug use. Of persons injecting drugs for at least 5 years, 60 percent to 80 percent 
are infected with HCV compared to about 30 percent infected with HIV.  The high rate of HCV 
infection among injection drug users is also reflected in the high rates (15 percent to 40 percent) 
of HCV infection found among incarcerated persons.  More than 80 percent of the nation’s 
estimated 1.7 million current injecting drug users have been incarcerated. 
Prior to the mid-1980's there was a 7 percent to 10 percent risk of non-A, non-B hepatitis 
(hepatitis C) from blood transfusion.  This risk declined by more than 50 percent between 1985 
and 1990 as a result of implementation of blood donor screening for HIV and surrogate testing for 
non-A, non-B hepatitis. In 1990, specific donor screening for HCV was implemented and by 
1992 the risk of HCV infection from a unit of transfused blood was reduced to one in 100,000. 
As of 2001, the risk of HCV infection from a unit of transfused blood is less than one per million 
transfused units. 
Clotting factor concentrates, which are plasma-derived products used to treat individuals with 
hemophilia, posed a high risk for HCV infection prior to the use of virus inactivation procedures 
that were introduced in 1985 and 1987. Except for one outbreak of hepatitis C from a single type 
of contaminated intravenous immunoglobulin, 
other plasma-derived products, including 
immune globulin for intramuscular 
administration, have not been associated with the 
transmission of HCV in the United States. 
Currently, all immune globulin products undergo 
a virus inactivation procedure or test negative for 
HCV prior to release. 
Sexual exposures account for about 15 percent of 
cases of hepatitis C. Although the risk for 
transmitting HCV infection through sexual 
intercourse is low, sex is a common behavior in  Figure 2. 
the general population, a substantial proportion of the adult population has had unprotected sex 
with multiple partners, and there are a large number of persons with HCV infection.  While other 
types of exposures are more likely to transmit HCV (e.g., transfusion from an infected donor), 
they account for a smaller proportion of infections because of the relatively small proportion of 
the population in whom these exposures have occurred. 
HCV is most efficiently transmitted by exposures that involve 

direct passage of blood through the skin, i.e., a percutaneous exposure.
 
Exposures resulting from hemodialysis, employment in the health care field, and birth to an HCV-
infected mother together account for about 5 percent of cases.  About 10 percent of people with 
HCV infection have no recognized source for their infection. 
While it is possible for HCV to be transmitted from any percutaneous exposure to blood, 
exposures such as tattooing, body piercing, or acupuncture have not been shown to place people 
at increased risk for infection. Higher rates of HCV infection are not found among persons with 
these exposures alone and these exposures are rarely reported among new cases of 
hepatitis C. 
Consequences of HCV infection.  About 15 percent to 25 percent of persons with acute hepatitis 
C resolve their infection without further problems.  The remainder develop a chronic infection 
and about 60 percent to 70 percent of these persons develop chronic hepatitis. Cirrhosis of the 
liver develops in 10 percent to 20 percent of persons with chronic hepatitis C over a period of 20-
30 years, and hepatocellular carcinoma (liver cancer) in 1 percent to 5 percent.  For individuals 
with cirrhosis, however, the rate of development of liver cancer might be as high as 1 percent to 4 
percent per year. 
Lower rates of complications have been reported from studies of persons who acquired infection 
as children. However, longer term follow-up studies are needed to assess lifetime consequences 
of chronic HCV infection in different populations, especially among children. 
Chronic liver disease is the tenth leading cause of death among adults in the United States.  It is 
estimated that 40 percent to 60 percent of chronic liver disease is due to hepatitis C and another 
 10 percent to 15 percent is due to chronic hepatitis B. HCV-associated chronic liver disease is the 
most frequent indication for liver transplantation 
among adults.  Additionally, because alcohol use is one of the most important contributing factors 
to progression of chronic liver disease among persons with hepatitis C, it is important to identify 
infected individuals as early as possible so that they can be counseled to limit alcohol 
consumption and be offered treatment if appropriate. 
Treatment for hepatitis C. In 1997, an NIH Consensus Development Conference established 
guidelines for the medical management of hepatitis C1, which have since been updated to reflect 
the evolving nature of antiviral therapy. A combination of alpha-interferon and ribavirin 
currently is the most effective therapy and achieves the sustained elimination of HCV infection 
for at least 6 months in 30 percent to 40 percent of patients. 
However, 10 percent to 20 percent of treated patients do not complete therapy because they 
experience significant side effects. In addition, some patients may have conditions, such as severe 
cirrhosis which prohibit treatment.  Current antiviral therapy is not licensed for patients below age 
18 years. 
HCV-associated chronic liver disease is the most frequent indication for liver 
transplantation among adults. 
Persons with chronic hepatitis C who continue to abuse alcohol are at risk for ongoing liver injury 
and antiviral therapy may be ineffective.  In addition, interferon therapy can be associated with 
relapse in people with a previous history of alcohol abuse; therefore, abstinence from alcohol is 
recommended during antiviral therapy. Interferon therapy should be considered with caution for 
patients who recently stopped alcohol abuse, and these patients require the support of alcohol 
treatment programs. 
Patients with hepatitis C on methadone treatment have been successfully treated with interferon. 
However, there is limited experience with treatment of persons who are recovered injection drug 
users or who are active injection drug users. In addition, there is the concern that active injection 
drug users are at risk for reinfection with HCV. When patients with past or continuing substance 
abuse are considered for antiviral treatment, such patients should receive drug treatment or care 
from substance abuse specialists or counselors. 
Drug treatment is an important adjunct to care for 
many persons with hepatitis C. 
Persons with HCV-related liver disease should be vaccinated against diseases that may produce 
further complications or increase their risk of death.  Susceptible persons with chronic liver 
disease should receive hepatitis A vaccine since they are at increased risk of death from liver 
failure if they get hepatitis A. All persons with chronic liver disease should be vaccinated 
1 National Institutes of Health. (1997) Management of Hepatitis C. March 24-26;15(3):1-41. 
http://odp.od.nih.gov/consensus/cons/105/105_statement.htm 
 annually against influenza and should receive pneumoccocal vaccine.  In addition, persons with 
continued risk factors for HBV infection should receive hepatitis B vaccine. 
Co-infection. Coinfection with HCV, HIV and/or HBV is currently recognized as a serious 
problem and is more likely to be found among injection drug users and persons treated for 
hemophilia before the availability of inactivated clotting factor concentrates.  Deaths from 
chronic hepatitis C among patients with HIV are expected to increase as advances with 
antiretroviral therapy extend the life span of these patients. Management of HIV infection in 
HCV co-infected patients generally is similar to that for patients with HIV alone, although there 
is some risk of liver toxicity from the antiretroviral drugs.  HCV coinfected patients should be 
evaluated to determine if they are candidates for antiviral treatment of
their chronic liver disease. Because treatment and medical management of co-infected patients is 
complicated and rapidly evolving, such patients are best managed by health care providers with 
experience in treating both HIV and HCV infection. More research is needed to determine the 
ideal management and treatment of co-infected individuals. 
Deaths from chronic hepatitis C among patients co-infected with HIV are 
expected to increase as antiretroviral therapy extends their life spans. 
Prevention and Control
 
The goals of hepatitis C prevention and control 
efforts are: 1) to reduce the incidence of new 
infections by reducing HCV transmission; and 
2) to reduce the risk of chronic liver disease in 
HCV-infected individuals through appropriate 
medical management and counseling.  
These goals can be achieved by identifying 
persons at risk for infection and providing them 
with education, risk reduction counseling, HCV 
testing, and appropriate medical services 
including substance abuse treatment.  Preventing 
or changing behaviors and activities that place 
persons at risk for HCV infection should reduce 
disease transmission.  Appropriate testing, 
medical management and substance abuse 
counseling and treatment should reduce the risk 
of chronic liver disease. Implementation of the 
following activities is required to achieve these 
prevention goals. 
Persons for whom routine HCV testing is 
recommended: 
‚ Persons who ever injected illegal drugs, 
including those who injected once or a 
few times many years ago. 
‚ Persons who received a blood transfusion 
or organ transplant before July 1992. 
‚ Persons who received clotting factor 
concentrates produced before 1987. 
‚ Persons who were ever on long-term 
dialysis. 
‚ Children born to HCV-positive women. 
‚ Healthcare, emergency medical, and 
public safety workers after needlesticks, 
sharps, or mucosal exposures to HCV-
positive blood. 
Identifying persons at risk for infection. Because of the large number of Americans infected 
with HCV, identification of these persons through testing is a high priority. Testing should be 
routinely offered to persons most likely to be infected with HCV.  In addition, anyone who wishes 
to know their HCV infection status should be provided the opportunity for testing.  In all 
instances, testing should be accompanied by appropriate counseling and referral for medical 
follow-up. 
To identify persons who should be counseled and tested for HCV, health care professionals in 
primary care, specialty, and public health settings should routinely question patients about risk 
factors for infection, including history of injecting drug use.  Current injecting drug users are 
often not seen in primary care or other traditional health care settings.  However, targeted 
outreach in other settings may be particularly effective in reaching this population. These settings 
include correctional institutions, drug treatment programs, programs for high risk youth, HIV 
counseling and testing sites, and STD clinics. 
Health care professionals in primary care, specialty, and public health settings 
should routinely question patients about risk factors for HCV infection. 
Persons infected with HCV because of medical risk factors (e.g., transfusion, hemophilia, chronic 
hemodialysis) should be identified by health care professionals and through educational efforts 
provided by patient organizations. Many of these persons have been tested for HCV and testing 
should be encouraged for those not previously tested. 
 
 
  
 
Health Education and Communication.  Achieving high levels of awareness concerning
 
hepatitis C prevention and maximizing the number of infected persons identified require
 
education and communication directed at health care and public health professionals, persons in
 
groups at risk for infection, and the general public. 

Health care professionals
 
Education of health care professionals requires:
 
•	 Continuing medical education programs such as found at www.cdc.gov/ncidod/diseases/hepatitis 
and development of clinical and public health practice guidelines to facilitate the 
incorporation of recommendations for the prevention of HCV infection and its consequences2 
into clinical and public health practice. 
•	 Development and dissemination of materials to aid health care professionals in identifying 
persons at risk for HCV infection during primary and specialty health care visits, at clinics 
that provide public health services, in drug outreach and substance abuse treatment programs, 
and in correctional health programs. 
•	 Periodic updates of guidelines for the diagnosis, treatment and prevention of hepatitis C and 
continuing medical education programs to disseminate this information at the local and 
national level. 
At-Risk Populations 
Development and distribution of educational messages for groups of persons at increased risk for 
infection should include persons transfused prior to July 1992; incarcerated populations; 
substance abusers including those in treatment and outreach programs; persons at risk for 
HIV/AIDS and STDs; and persons attending other community health programs. 
HCV prevalence among prison inmates is 3-5 times greater 
than in the general population. 
Recent data indicate that prevalence of HCV infection among incarcerated populations is 3-5 
times greater than prevalence in the general population.  In addition, messages need to be 
developed for individuals who may have experimented with injecting drug use only in the distant 
past, since these persons may not regard themselves as being at risk for infection because they 
did not become long-term or habitual users.  
General Public 
Culturally-sensitive, multimedia advertising and education in English, Spanish and other 
languages are needed to increase public awareness about HCV infection; risk factors for 
2 Centers for Disease Control and Prevention. (1998) Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and 
HCV-Related Chronic Disease. MMWR;47 (No. RR-19). ftp://ftp.cdc.gov/pub/Publications/mmwr/rr/rr4719.pdf
   
infection; the need for counseling, testing, and medical management to prevent chronic liver 
disease; and how to differentiate hepatitis C from other types of hepatitis. 
These include: 
•	 Materials for use in clinic and other health care waiting rooms, correctional settings, drug 
treatment and prevention programs, and outreach programs for persons at risk for HIV/AIDS. 
•	 A full-time, national hepatitis hotline and information line (1-888-4HEP-CDC) that provides 
both recorded information and interactive counseling. 
•	 A web site (www.cdc.gov/hepatitis) that provides information about frequently asked 
questions, patient and provider educational materials, and hyperlinks to other sites which 
provide information on viral hepatitis. 
•	 Regional or local sources that provide accurate 
information to concerned persons or groups in a 
culturally sensitive manner and in the language that 
is best understood by the requestor. 
Counseling, Testing, and Medical Referral.
Identification of persons at risk for HCV infection 
should initiate both counseling and testing, however, 
counseling can be performed without testing. 
Counseling services must be available in a wide variety 
of settings, including those that provide primary and 
specialty health care services in the private and public 
sectors. Because injection drug use is the primary risk 
factor for infection, counseling and testing 
must be available for clients of programs for the 
prevention and treatment of substance abuse, 
HIV/AIDS, and STDs and for persons in correctional 
Figure 3: Public service messages directed tosettings. persons at risk for HCV infection from a 
transfusion.
Individuals with ongoing risk factors for HCV infection 
should receive client-centered education and counseling 
which concentrates on changing behaviors that place them at risk for infection.  These behaviors 
include substance abuse, sharing of injection drug use equipment, and high risk sexual practices. 
In addition to risk reduction counseling, at-risk persons should be referred to appropriate harm 
reduction programs, including treatment for substance abuse and syringe and 
needle exchange sites. In addition, these persons should receive hepatitis A and hepatitis B 
vaccination. 
At-risk persons should be immunized with hepatitis A and 
hepatitis B vaccine, as appropriate. 
 HCV testing is required to identify infected persons at risk for chronic liver disease and for 
transmitting HCV to others. When testing is performed, HCV positive individuals require: 1) 
counseling to reduce the risk of HCV transmission to others;  2) medical referral to determine the 
extent of their liver disease; and, if appropriate, 3) counseling to limit their alcohol intake, 
antiviral treatment, immunization with hepatitis A, hepatitis B, pneumococcal and influenza 
vaccines, and treatment for alcohol or drug abuse.  HCV negative persons with ongoing risk 
factors require counseling concerning ways to reduce their risk for infection, referral to 
substance abuse treatment if appropriate, and immunization with hepatitis A and hepatitis B 
vaccines. 
Hepatitis C counseling should be performed in a consistent, client-centered structure. 
Counseling materials are currently being developed and have not been extensively evaluated for 
effectiveness. 
Integration of HCV counseling and testing into existing programs may enhance 
identification of persons at risk for HIV and HBV infection.
Based on current experience in counseling persons at risk for HCV infection or with hepatitis C, 
a wide variety of information must be available to the counselor.  This includes information on 
harm reduction for persons at continued risk for infection, the meaning of positive test results, 
the importance of medical evaluation for chronic liver disease, the health outcomes of HCV 
infection and hepatitis C, the risk of transmission to family members or other contacts, and 
immunization to prevent infection with hepatitis A, hepatitis B, and other diseases. 
Staff training is required for effective hepatitis C counseling and health education.While many 
hepatitis C prevention messages are similar to those for HIV, several aspects of hepatitis C 
prevention are different and must be integrated into counseling and testing activities to best meet 
the needs of the client. 
In addition, culturally appropriate health education materials will be required for use by health 
care providers, and patient support groups. 
While the capacity for HCV (antibody) testing exists in all blood banks and most hospital and 
private diagnostic laboratories, a recent survey3 showed that less than 50 percent of state and 
local public health laboratories have the capacity to perform any type of HCV testing.  As with 
HIV testing, HCV antibody testing requires the laboratory capacity to perform supplemental 
testing to 
confirm that the initial test result represents a “true positive” and that the client does not receive 
incorrect information concerning his or her HCV infection status.  To determine whether a 
person has chronic HCV infection requires nucleic acid testing for HCV RNA (‘PCR testing’). 
While this type of testing was only available in research laboratories several years ago, it is now 
becoming better standardized and available in many diagnostic laboratories. 
3Association of Public Health Laboratories. (unpublished data) 
Less than 50 percent of state and local public health laboratories have the 
capacity to perform HCV testing. 
Counseling and testing sites should provide referral for the medical evaluation of persons who 
test HCV-positive. The initial medical evaluation of an HCV positive individual does not 
require a specialist (e.g., hepatologist, gastroenterologist). 
However, the referral physician should be familiar with the interpretation of the diagnostic work-
up required to ascertain whether a patient has chronic HCV infection and evidence of liver 
disease. In addition, the physician should have contact with specialists expert in the treatment 
and management of chronic hepatitis C. 
Integration of Hepatitis C Prevention into Other Prevention Services.   The similar modes of 
transmission of HIV, HBV and HCV present a unique opportunity to provide prevention services 
at a single client visit. Integration of services to prevent bloodborne viral infections is a 
relatively new concept. There is limited experience with combining counseling, testing, 
prevention, immunization, and treatment services for these diseases in  HIV/AIDS prevention 
sites, STD clinics, drug treatment sites, and correctional health programs. However, data from 
several demonstration projects indicate that integration of HCV counseling and testing into 
existing public health programs is feasible and may enhance identification of persons with risk 
behaviors for other bloodborne virus infections, such as HIV and HBV. 
 Surveillance and Research 

Surveillance.  Surveillance is essential to determine the effectiveness of national, state, and local 
hepatitis C prevention efforts.  However, surveillance for hepatitis C is complicated by the 
absence of a laboratory test that can differentiate newly acquired infections from infections 
acquired in the past. Although acute hepatitis (i.e., clinical illness) is reportable in all states, 
only a few states conduct surveillance for acute cases of hepatitis C to monitor disease incidence. 
However, approximately 30 states have requirements for reporting of HCV positive laboratory 
tests, most of which represent persons with resolved or chronic HCV infection. 
The current challenge is to determine how to utilize HCV positive laboratory reports to monitor 
trends in new infections, evaluate the effectiveness of testing and counseling efforts, and identify 
missed opportunities for hepatitis C prevention.  Only a few states maintain a database of 
laboratory reports, and most do not collect patient-specific information concerning risk factors 
for infection or medical follow-up. 
The challenge is how to use laboratory-based reports of HCV to monitor disease 
trends and the effectiveness of prevention programs. 
Development and maintenance of confidential state databases of persons with HCV infection, 
which contain information on risk factors for infection and medical follow-up, could provide a 
means to determine the effectiveness of prevention programs.  Such surveillance could determine 
whether persons with certain risk factors for infection are more or less likely to be identified and 
tested, and whether HCV positive persons have received counseling and medical referral. 
Making surveillance systems in all states comparable with respect to data quality and case 
definitions would greatly facilitate targeting and assessment of prevention programs. 
National trends in new cases of infectious disease are monitored by CDC’s National Notifiable 
Disease Surveillance System (NNDSS).  However, for hepatitis C, the data reported by states are 
not reliable because most reports to NNDSS represent persons with chronic or resolved HCV 
infection and not acute disease. To determine national trends in disease incidence and risk 
factors for infection, CDC has relied on intensive sentinel surveillance conducted in 6 counties4 -
- the Sentinel Counties Study of Viral Hepatitis. Until such time that persons with acute HCV 
infection can be identified either through a single diagnostic test or some combination of tests 
(e.g., antibody testing and liver enzyme levels), estimates of HCV infection incidence will 
primarily depend on data from the Sentinel Counties Study.  
CDC uses several other surveillance systems to monitor trends in HCV infection.  NHANES III 
identified the high prevalence of HCV infection in the United States and showed that African-
Americans had a higher prevalence of HCV infection than other racial/ethnic groups.  Testing of 
subsequent NHANES will be used to monitor infection prevalence in different populations of 
Americans.  Surveillance for chronic liver disease has been established in several of CDC’s 
Emerging Infections Program sites.  This chronic liver disease surveillance system will enhance 
4Alter MJ, Hadler SC, Judson FN, et al. (1990) Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C 
virus antibody.  JAMA; 264: 2231-2235. 
understanding of the natural history of HCV infection, monitor national trends in chronic 
hepatitis C, and provide estimates of the contribution of HCV infection to chronic liver disease 
in the United States. 
Epidemiologic and Laboratory Investigations.  A number of unanswered questions 
significantly impact the direction of hepatitis C prevention and control activities.  Priority areas 
in which studies are underway or in the planning stages include those that determine: 1) 
incidence and risk factors for HCV transmission among household contacts of infected persons; 
2) risk factors for transmission from mother to infant at birth; 3) risk of infection from intranasal 
cocaine use, tattooing, and body-piercing; 4) prevalence and incidence of infection in 
incarcerated populations; 5) risk of infection among steady heterosexual partners of HCV-
infected persons; 6) risk factors for infection among persons on chronic hemodialysis; 7) risk for 
infection among persons with occupational exposure to HCV and effectiveness of therapy during 
acute infection; 8) the dynamics of HCV acquisition among injection drug users and the 
effectiveness of harm reduction strategies in preventing infection;  9) the frequency and 
consequences of infection with multiple HCV strains among injection drug users; and 10) 
development and performance of rapid screening tests for HCV infection. 
  
 
Implementation of the National Hepatitis C Prevention Strategy 
CDC’s implementation plan for the National Hepatitis C Prevention Strategy comprises the 
following elements: 
•	 Communication of information about hepatitis C to health care and public health 
professionals and education of the public and persons at risk for infection; 
•	 Integration of hepatitis C prevention and control activities into State and local public health 
programs to identify, counsel, and test persons at risk for HCV infection; provide referral for 
medical evaluation of those found to be infected; and conduct outreach and community-
based activities to address practices that put people at risk for HCV infection; 
•	 Surveillance to monitor acute and chronic disease trends and evaluate the effectiveness of 
prevention and medical care activities; and  
• Epidemiologic and laboratory investigations to better guide prevention efforts. 
Timely implementation of these prevention activities at the national, state, and local levels can 
be expected to achieve a reduction in hepatitis C mortality and morbidity. 
Communication of Information about Hepatitis C. 
Education of health care professionals:  Because hepatitis C was only recently described, health 
care professionals are often not aware of current information concerning diagnosis, medical 
management, and prevention of this disease.  Education of health care professionals about 
hepatitis C -- pathogenesis, diagnosis, medical management, epidemiology, and prevention --
was the first activity undertaken as part of the National Hepatitis C Prevention Strategy. 
Because knowledge about hepatitis C is complex and rapidly evolving, ongoing access to the 
latest information must be provided and requires commitment of resources for development and 
distribution of continuing education programs and materials for physicians, nurses, and other 
health care professionals. A wide range of educational materials must continue to be developed 
and distributed by CDC in partnership with other governmental, non-governmental, professional 
and voluntary health organizations. These materials include brochures and monographs; articles 
in professional journals; web-based and other distance learning formats; and symposia, grand 
rounds, and workshops. 
Good clinical and public health practice is based on the availability of recommendations and 
guidelines from professional organizations, CDC, or other government agencies.  Consultants 
meetings will be held to develop and update recommendations for the prevention and 
management of 
hepatitis C in various populations and settings, including correctional institutions, hemodialysis 
units5, and drug treatment and prevention programs. 
Because hepatitis C was only recently described, health care professionals 
often are not aware of current information concerning diagnosis, 
medical management, and prevention.
State-funded programs have requested technical assistance from CDC for materials to train 
5 Centers for Disease Control and Prevention. (2001) Recommendations for preventing transmission of infections among chronic hemodialysis 
patients. MMWR;50 (No. RR-5): 28-29. http://www.cdc.gov/mmwr/PDF/rr/rr5005.pdf 
  
 
counselors. These materials are in the final 
stages of development, along with a hepatitis 
training curriculum for the national STD 
Prevention and Training Center network. 
There is need for the further development and 
distribution of a wide range of client-centered 
counseling materials for use in settings where 
persons at risk for HCV infection are identified 
(e.g., HIV/AIDS counseling and testing sites, 
STD clinics, drug treatment facilities, 
correctional facilities). 
Education of the general public and groups at 
increased risk for infection: 
CDC has joined with a number of non-
governmental organizations to ensure 
widespread distribution of hepatitis C health 
education and prevention messages. 
Providing resources to these and other partners 
will continue to ensure that health education 
materials and messages consistent with CDC’s 
recommendations are distributed to the public 
as well as to persons in groups at increased risk 
for infection. Public service advertising and 
media outreach in various formats are needed to 
increase public awareness of the importance of 
hepatitis C prevention and control. Continued 
formative research is needed to determine what 
messages and formats might best reach 
intended audiences, such as past and present 
CDC Partners in Viral Hepatitis
 
Prevention, 1997-2001
 
American Liver Foundation 
www.liverfoundation.org 
American Social Health Association 
www.ashastd.org 
Council of State and Territorial 
Epidemiologists 
http://www.cste.org/ 
Health Care Education and Training 
www.hcet.org 
Hepatitis Foundation International 
www.hepfi.org 
Immunization Action Coalition 
www.immunize.org 
JSI Research & Training Institute 
www.jsi.com 
National Alliance of State/Territorial AIDS 
Directors 
www.nastad.org 
National Association of City/County Health 
Officials 
www.naccho.org
National Commission on Correctional 
Health Care 
www.ncchc.org
National Minority AIDS Council 
www.nmac.org 
Parents of Kids w/ Infectious Diseases 
www.pkids.org
injecting drug users and individuals with high-risk sexual activity. Print materials and public 
service advertising for persons at risk for transfusion-acquired HCV infection have been 
developed and are being distributed, but their effectiveness remains to be evaluated.  Education 
and advertising materials and campaigns will be developed to reach persons in other risk groups. 
CDC’s hepatitis website regularly provides updated information for both health professionals 
and the public and links with partners for additional information.  In addition, CDC’s Hepatitis 
Information Line and HotLine provide both “live” and recorded information in both English and 
Spanish. 
State-based Hepatitis C Prevention and Control Programs. Hepatitis C counseling and 
testing programs need to be implemented at the state and local levels.  Although a recent survey 
of local health officers showed that 87 percent of city and county health departments provide 
education about HIV/AIDS and 77 percent provide HIV testing, less than 50 percent provide 
 hepatitis C counseling and only 23 percent provide HCV testing6. 
Currently, no federal funding is available to support nationwide establishment of 
hepatitis C counseling and testing services at the state or local level. In response to this lack of 
federal funding, a number of state and local health departments have funded hepatitis C 
counseling and testing projects. 
Most of these local programs have relied heavily on technical support and materials developed 
by CDC. However, prevention services need to be expanded, especially for disenfranchised 
populations and populations with health disparities (e.g., African-Americans, Native Americans), 
which can only be assured by a national program. 
Less than 50 percent of local health departments provide hepatitis C 
counseling and only 23 percent provide HCV testing. 
A major goal of the National Hepatitis C Prevention Strategy is funding of a ‘Hepatitis C 
Coordinator’ for every state and large metropolitan health department to meet the expressed 
needs of state and local public health officials. The Hepatitis C Coordinator provides the 
management, networking, and technical expertise required for successful integration of hepatitis 
C prevention and control activities into existing public health programs (Figure 4).  Coordinators 
assist state or local health departments in: 1) 
identifying public health and clinical activities in 
which HCV counseling and testing should be 
incorporated; 2) ensuring training of health care 
professionals in effective hepatitis C prevention 
activities; 3) developing the capacity to provide 
HCV testing through public health or private 
diagnostic laboratories; 4) identifying sources for 
appropriate medical referral of HCV positive 
persons; 5) ensuring appropriate surveillance for 
HCV infection; and 6) evaluating the effectiveness 
of HCV prevention activities. Figure 4. 
Broad implementation of hepatitis C prevention activities has been greatly facilitated by the 
development of a State hepatitis C/viral hepatitis prevention plan.  These plans have provided the 
road map for prioritizing development of prevention activities, integrating hepatitis prevention 
activities into existing public health programs, and obtaining resources to achieve 
implementation of prevention activities.  A number of approaches have been used to develop 
such plans, including convening special commissions or consensus meetings, or using 
consultants. Key to development of a successful plan is inclusion of stakeholders and experts 
involved in viral hepatitis prevention and control from fields which include: public health, 
infectious disease, immunization, correctional health, drug and substance abuse treatment, 
HIV/AIDS counseling and testing, STD prevention and treatment, mental health, public health 
nursing, clinical medicine (primary care, hepatology, gastroenterology), laboratory medicine, 
6 National Association of City and County Health Officers. (submitted for publication) Hepatitis C/HIV Needs Assessment. 
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 patient support and advocacy, health communication and education, health care financing, and 
public health policy. Although a number of States have now developed such plans, technical 
assistance and resources are needed to assist those States without plans. 
While prevention of all bloodborne virus infections (HIV, HCV, HBV) is a major goal of the 
National Hepatitis C Prevention Strategy, there is limited experience with the integration of 
hepatitis C and hepatitis B prevention activities into public health programs for persons at risk 
for bloodborne viral infections, including incarcerated persons7. Demonstration projects to 
examine the feasibility and operational aspects of integrating hepatitis C prevention into existing 
public health and correctional health programs were first funded by CDC in FY 1999, were 
expanded to include several county and city health departments in FY 2000, and should be 
further expanded to include state-wide projects.  Demonstration projects include activities to 
prevent HCV, HBV, and HIV infection, such as counseling, testing, and medical referral for 
infected persons, and hepatitis B and hepatitis A immunization.  Critical to the implementation 
of integrated prevention activities is funding for public health laboratories to provide HCV 
testing for persons served in the public sector and for immunization with hepatitis B and 
hepatitis A vaccines of at-risk persons.
 CDC’s annual National Hepatitis Coordinator meeting, which previously has brought together 
persons involved with the prevention of HBV infection at the state and local levels (e.g, hepatitis 
B coordinators, state immunization directors, STD program managers), will be expanded to 
facilitate the sharing of information gained from federally and locally funded hepatitis C 
prevention activities. 
Surveillance
States that require reporting of persons who test HCV positive need resources to establish, 
maintain, and analyze information on infected persons for purposes of disease surveillance. 
These resources would support use of state surveillance databases to evaluate the effectiveness 
of prevention programs by determining: 1) the proportion of the population with hepatitis C that 
has been identified; 2) missed opportunities for identification of persons with selected risk 
factors for HCV infection; and 3) whether persons reported to state surveillance systems have 
received counseling, medical referral, and appropriate medical management.  For states without 
HCV surveillance, CDC would offer assistance in establishing surveillance systems for 
evaluating the effectiveness of their hepatitis C prevention programs. 
In addition to state-based surveillance, CDC must continue to maintain several other surveillance 
systems including: 1)  the Sentinel Counties Study of Viral Hepatitis to determine trends in 
incidence of acute hepatitis C and other types of viral hepatitis, and risk factors for infection; 2) 
testing of participants in NHANES to determine age-specific trends in prevalence of HCV 
infection;  and 3) sentinel surveillance for chronic liver disease to determine trends in chronic 
hepatitis C. 
7Association of State and Territorial Health Officers. (2000) Hepatitis C & Incarcerated Populations: The Next Wave for Correctional Health 
Initiatives. 
 Epidemiologic and Laboratory Investigations 
Research to answer questions which impact hepatitis C prevention and control is an important 
component of the National Hepatitis C Prevention Strategy and prevention of new HCV 
infections probably is the greatest challenge. The majority of new HCV infections occur among 
persons who inject illegal drugs and the risk of HCV infection among this group is several-fold 
greater than the risk of HIV infection. High priority must be given to studies that determine 
those activities among active injection drug users which facilitate HCV transmission and the 
development of interventions which interrupt transmission.  In addition, prevention of HCV 
infection must become the marker of success of community-based interventions to prevent drug 
use among persons at high risk for this behavior.  
Priority also must be given to studies which answer questions related to other risk factors for 
HCV infection in order to improve counseling messages and to devise effective prevention 
activities. These include studies to quantify risk for infection following sexual exposure, the risk 
of transmission from tattoos or body piercing obtained in various settings, risk from non-
injection drug use (e.g., cocaine use), risk of infection following occupational needlestick 
exposure, and risk of perinatal HCV infection following obstetric interventions or complications. 
Laboratory tests that differentiate acute from chronic HCV infection or rapid diagnostic tests that 
could be used in outreach settings would greatly improve identification of persons with HCV 
infection and improve prevention and control activities. 
